• Data from two Phase 3 studies in patients with cSSSI, or data from two Phase 3 studies in patients with cIAI, were used to assess the predictive performance of a population PK model previously developed using data from two Phase 2 studies (one each cIAI and cSSSI).
• The study designs and tigecycline dosing regimens administered over 14 days are summarized in Table 1 .
• Based on the clinical judgment of the investigator, patients enrolled in these studies could have been discharged from the hospital after 3 days of inpatient therapy and received IV tigecycline doses at home.
• The actual time of infusion termination was only recorded for the Phase 2 studies; the protocol-specified duration of infusion was therefore assumed for each Phase 3 study.
• Blood (5 mL) was generally collected prior to dosing, at the end-of-infusion (either 0.5 or 1 h), and at 3 and 6 h post-start of infusion on the day before or day of discharge from the study unit.
• Serum tigecycline concentrations were determined using a validated LC/MS/MS method with an LLOQ of 10 ng/mL.
METHODS

Data
• The Phase 3 cSSSI dataset consisted of 84 serum tigecycline concentrations obtained from 24 patients; the cIAI patient dataset consisted of 583 serum tigecycline concentrations from 155 patients.
• Patient demographics (Table 3 ) and the range of tigecycline serum concentrations and sampling times (Figure 1) were similar between the two Phase 3 datasets and the Phase 2 model development dataset.
Application of the Population PK Model to the Phase 3 Data
• The population PK model provided an adequate and relatively unbiased fit to both Phase 3 datasets based upon examination of goodness-of-fit plots.
• The model had a slightly higher tendency to under predict concentrations at the end of the infusion for both Phase 3 datasets than for the model development dataset. This may be due to the fact that the actual infusion duration was not recorded and required making the assumption that tigecycline was infused over the protocol-specified time period.
Predictive Performance Assessment
• Individual predicted AUC 0-12 values were in general agreement with the observed AUC 0-12 values, and no strong biases were observed over the range of observed AUC 0-12 values for each dataset (Figure 2 ). • Summary statistics for PE% and ⎪PE⎪% for AUC 0-12 were calculated for each dataset and are provided in Table 4 .
• Although the population PK model appeared to slightly under predict AUC [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] for patients in each dataset, AUC 0-12 was generally unbiased (median PE% ranged from -1.60 to -3.78%) and acceptably precise (median ⎪PE⎪% ranged from approximately 3 to 4%) across datasets.
RESULTS
• A previously developed population PK model for tigecycline based on Phase 2 data provided an acceptably precise and relatively unbiased fit to the sparse-sampling data from Phase 3 trials of patients with cIAI and cSSSI without the need for further model refinement.
• Individual predicted steady-state AUC 0-12 estimates in Phase 3 patients were also acceptably precise and unbiased and will be utilized in additional exposure-response analyses for safety and efficacy in the respective patient populations.
CONCLUSIONS
Purpose
Tigecycline is a novel glycylcycline antibiotic demonstrating broad-spectrum in vitro activity. A previously developed population pharmacokinetic (PK) model was utilized to generate individual predicted AUC 0-12 estimates in patients with complicated skin and skin-structure infections (cSSSI) or complicated intra-abdominal infections (cIAI) in Phase 3 studies for use in future exposure-response analyses of safety and efficacy.
Methods
In 4 Phase 3 studies, tigecycline was infused over 0.5 hour (cIAI patients, n=155) or 1 hour (cSSSI patients, n=24) as a 100-mg loading dose followed by 50 mg every 12 hours for up to 14 days. A population PK model (2-compartment, zero-order input and first-order elimination; clearance as a function of creatinine clearance, weight, and sex) was previously developed using steady-state data from Phase 2 studies of patients with cSSSI and cIAI. The final Phase 2 parameter estimates were used as population priors. The model was applied separately to the Phase 3 cSSSI and cIAI data in NONMEM ® to estimate empirical Bayesian PK parameters. Model performance was evaluated for both datasets by assessing goodness-of-fit, bias (PE%), and precision (⎪PE⎪%) for individual predicted tigecycline concentrations and steady-state AUC 0-12 values.
Results
The patient populations in Phase 2 and 3 cSSSI and cIAI studies had similar demographic characteristics and steady-state tigecycline concentrations. Goodness-of-fit plots revealed that the Phase 2 model provided a relatively unbiased fit to both Phase 3 datasets: the median PE% was ± 3% and 4%, while ⎪PE⎪% was within 10% and 4% for the individual predicted tigecycline concentrations and AUC 0-12 values, respectively.
Conclusions
The feasibility of using a previously developed population PK model to predict individual AUC 0-12 in a new population with similar demographic and pharmacokinetic characteristics was explored. The Phase 2 population PK model for tigecycline provided an acceptably precise and relatively unbiased fit to the Phase 3 data, and resulted in unbiased estimates of AUC [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 
Population PK Model
• The population PK model was a 2-compartment model with zero-order input and first-order elimination and clearance modeled as a function of creatinine clearance (CrCL), weight, and gender ( Table 2) .
Application of the Population PK Model to the Phase 3 Data
• The population PK model was applied separately to the pooled Phase 3 data from patients with cSSSI or cIAI.
• All population mean parameters were fixed to the final Phase 2 estimates.
• Bayesian PK parameter estimates were obtained for each patient in both datasets.
• Goodness-of-fit was assessed graphically for both datasets.
Predictive Performance Assessment
• Model performance was evaluated for each dataset by comparing the bias and precision of the steady-state AUC 0-12 values computed from individual predicted concentrations relative to steady-state AUC 0-12 values computed from observed concentrations.
• Patients were included in this assessment provided they:
• contributed at least four observed concentrations per patient;
• had a sample collected prior to dosing (e.g., trough) and another sample collected within 0.25 h of termination of the infusion; and • had a trough sample collected at 12 ± 0.5 h following a dose (trough concentrations were duplicated for use as an observed concentration at the end of the dosing interval).
• Bayesian PK parameter estimates were used to predict tigecycline concentrations at each of the observed sampling times.
• Observed and individual predicted steady-state AUC 0-12 values were calculated using the mixed log-linear trapezoidal rule and were plotted to assess potential biases.
• The difference between the observed and individual predicted AUC [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] was also calculated as a percentage of the observed AUC 0-12 . The distributions of these prediction error percents (PE%) and the ⎪PE⎪% were evaluated as measures of bias and precision, respectively.
